BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 11753957)

  • 1. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal.
    van Haaften-Day C; Shen Y; Xu F; Yu Y; Berchuck A; Havrilesky LJ; de Bruijn HW; van der Zee AG; Bast RC; Hacker NF
    Cancer; 2001 Dec; 92(11):2837-44. PubMed ID: 11753957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevation of multiple serum markers in patients with stage I ovarian cancer.
    Woolas RP; Xu FJ; Jacobs IJ; Yu YH; Daly L; Berchuck A; Soper JT; Clarke-Pearson DL; Oram DH; Bast RC
    J Natl Cancer Inst; 1993 Nov; 85(21):1748-51. PubMed ID: 8411259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OVX1 as a marker for early stage endometrial carcinoma.
    Xu FJ; Yu YH; Daly L; Anselmino L; Hass GM; Berchuck A; Rodriguez GC; Soper JT; Clarke-Pearson DL; Hollis D
    Cancer; 1994 Apr; 73(7):1855-8. PubMed ID: 8137210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer.
    Zhang Z; Yu Y; Xu F; Berchuck A; van Haaften-Day C; Havrilesky LJ; de Bruijn HW; van der Zee AG; Woolas RP; Jacobs IJ; Skates S; Chan DW; Bast RC
    Gynecol Oncol; 2007 Dec; 107(3):526-31. PubMed ID: 17920110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures.
    Xu FJ; Yu YH; Daly L; DeSombre K; Anselmino L; Hass GM; Berchuck A; Soper JT; Clarke-Pearson DL; Boyer C
    J Clin Oncol; 1993 Aug; 11(8):1506-10. PubMed ID: 8336189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection.
    Berek JS; Bast RC
    Cancer; 1995 Nov; 76(10 Suppl):2092-6. PubMed ID: 8635006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum level of macrophage colony-stimulating factor as a marker for gynecologic malignancies.
    Suzuki M; Ohwada M; Sato I; Nagatomo M
    Oncology; 1995; 52(2):128-33. PubMed ID: 7854772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematopoietic cytokines as tumor markers in gynecological malignancies. A multivariate analysis in epithelial ovarian cancer patients.
    Lawicki S; Gacuta-Szumarska E; Będkowska GE; Szmitkowski M
    Growth Factors; 2012 Dec; 30(6):357-66. PubMed ID: 22988839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
    Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML
    Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of combined use of macrophage colony-stimulating factor and squamous cell carcinoma antigen as a selective diagnostic marker for squamous cell carcinoma arising in mature cystic teratoma of the ovary.
    Suzuki M; Tamura N; Kobayashi H; Ohwada M; Terao T; Sato I
    Gynecol Oncol; 2000 Jun; 77(3):405-9. PubMed ID: 10831350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions.
    Skates SJ; Horick N; Yu Y; Xu FJ; Berchuck A; Havrilesky LJ; de Bruijn HW; van der Zee AG; Woolas RP; Jacobs IJ; Zhang Z; Bast RC
    J Clin Oncol; 2004 Oct; 22(20):4059-66. PubMed ID: 15381683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is OVX1 a suitable marker for endometrial cancer?
    Beck EP; Wagner M; Anselmino L; Xu F; Bast RC; Jaeger W
    Gynecol Oncol; 1997 May; 65(2):291-6. PubMed ID: 9159340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined use of biomarkers for detection of ovarian cancer in high-risk women.
    Donach M; Yu Y; Artioli G; Banna G; Feng W; Bast RC; Zhang Z; Nicoletto MO
    Tumour Biol; 2010 Jun; 31(3):209-15. PubMed ID: 20393825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macrophage colony-stimulating factor as a tumor marker for epithelial ovarian cancer.
    Suzuki M; Ohwada M; Aida I; Tamada T; Hanamura T; Nagatomo M
    Obstet Gynecol; 1993 Dec; 82(6):946-50. PubMed ID: 8233270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coordinate elevation of serum markers in ovarian cancer but not in benign disease.
    Bast RC; Knauf S; Epenetos A; Dhokia B; Daly L; Tanner M; Soper J; Creasman W; Gall S; Knapp RC
    Cancer; 1991 Oct; 68(8):1758-63. PubMed ID: 1913520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of CA 125 and CA72-4 in management of patients with epithelial ovarian cancer.
    Fayed ST; Ahmad SM; Kassim SK; Khalifa A
    Dis Markers; 1998 Nov; 14(3):155-60. PubMed ID: 10427474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased serum levels of macrophage colony-stimulating factor in ovarian cancer.
    Xu FJ; Ramakrishnan S; Daly L; Soper JT; Berchuck A; Clarke-Pearson D; Bast RC
    Am J Obstet Gynecol; 1991 Nov; 165(5 Pt 1):1356-62. PubMed ID: 1957862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer.
    Hurteau JA; Woolas RP; Jacobs IJ; Oram DC; Kurman CC; Rubin LA; Nelson DL; Berchuck A; Bast RC; Mills GB
    Cancer; 1995 Nov; 76(9):1615-20. PubMed ID: 8635066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The application value of the detection of the level of tissue polypeptide antigen, ovarian cancer antigen X1, cathepsin L and CA125 on the diagnosis of epithelial ovarian cancer.
    Lv XL; Zhu Y; Liu JW; Ai H
    Eur Rev Med Pharmacol Sci; 2016 Dec; 20(24):5113-5116. PubMed ID: 28051260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretreatment serum levels of CA-125, carcinoembryonic antigen, tissue polypeptide antigen, and placental alkaline phosphatase, in patients with ovarian carcinoma, borderline tumors, or benign adnexal masses: relevance for differential diagnosis.
    Tholander B; Taube A; Lindgren A; Sjöberg O; Stendahl U; Kiviranta A; Hallman K; Holm L; Weiner E; Tamsen L
    Gynecol Oncol; 1990 Oct; 39(1):16-25. PubMed ID: 2227569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.